Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Excretion Balance and Metabolism of 14C-BIRB 796 BS in Healthy Males
NCT02211885Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Oct 2002
- Primary completion
- Nov 2002
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of doramapimod in Crohn's disease, rheumatoid arthritis (RA) and psoriasis, sponsored by Boehringer Ingelheim. Primary endpoints: Cumulative amount of 14C-BIRB 796 BS radioactivity excreted in feces up to 5 days, Cumulative amount of 14C-BIRB 796 BS radioactivity excreted in urine up to 5 days and 16 more. Started Oct 2002; status: completed.
02
Drugs
doramapimod
03
Conditions
Crohn's diseaserheumatoid arthritis (RA)psoriasis
Beyond the preview
Go deeper on NCT02211885.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02211885.